{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-068817","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2024-06-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.243782+00:00","generated_at":"2026-06-01T05:51:11.392423+00:00","sec_items":["5.07","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Sagimet reports positive FASCINATE-2 Phase 2b data; denifanstat meets primary endpoints in MASH","bullets":["Primary endpoint: MASH resolution with ≥2-point NAS reduction without worsening fibrosis: 38% denifanstat vs 16% placebo (p=0.0035) in ITT.","Fibrosis improvement ≥1 stage without worsening MASH: 30% vs 14% placebo (p=0.0199) in ITT; 49% vs 13% in F3 subgroup (p=0.0032).","Fibrosis improvement ≥2 stages in mITT: 20% vs 2% placebo (p=0.0065); 34% vs 4% in F3 subgroup (p=0.0050).","No treatment-related SAEs; most AEs mild/moderate. TEAE discontinuation 19.6% denifanstat vs 5.4% placebo.","Company plans to initiate Phase 3 registrational program for denifanstat in MASH with fibrosis in H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-068817","json":"https://secwatch.observer/filing/0001104659-24-068817.json","markdown":"https://secwatch.observer/filing/0001104659-24-068817.md","text":"https://secwatch.observer/filing/0001104659-24-068817.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000110465924068817/0001104659-24-068817-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000110465924068817/tm2416614d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:51:11.392423+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}